Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: a randomized,...

Area of Science:

• Neuroscience
• Psychiatry
• Medical Devices

Background:

• Treatment-resistant depression (TRD) poses a significant clinical challenge.
• Augmentation therapies are crucial for improving treatment outcomes in TRD.
• Transcranial Pulsating ElectroMagnetic Fields (T-PEMF) is an emerging non-invasive neuromodulation technique.

Purpose of the Study:

• To compare the efficacy of twice-daily versus once-daily Transcranial Pulsating ElectroMagnetic Fields (T-PEMF) as augmentation therapy for TRD.
• To evaluate symptom remission rates after 8 weeks of T-PEMF treatment.
• To assess the impact of T-PEMF dosage frequency on depression symptom severity.

Main Methods:

• A double-blind, randomized trial was conducted using a self-treatment T-PEMF device.
• Patients with TRD received either one or two 30-minute T-PEMF sessions daily.
• Remission was defined as a Hamilton Depression Scale (HAM-D17) score of 7 or less.

Main Results:

• After 8 weeks, remission rates were 73.5% for once-daily and 67.7% for twice-daily T-PEMF.
• No significant difference in remission rates was observed between the two dosage frequencies.
• Both groups showed improved well-being and better toleration of existing antidepressant medication.

Conclusions:

• The high remission rate in T-PEMF augmentation for TRD is not dependent on dose frequency (once vs. twice daily).
• Extending the treatment duration from 5 to 8 weeks significantly contributed to the observed remission rates.
• T-PEMF appears to be a well-tolerated augmentation strategy for treatment-resistant depression.